SequelSEC

Kraig Biocraft Laboratories, Inc. KBLB

Plastic Material, Synth Resin/Rubber, Cellulos (No Glass) · CIK 0001413119 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$401.62K
Fiscal year ended 2018-12-31
Operating income
-$959.95K
Fiscal year ended 2018-12-31
Free cash flow
-$246.45K
Fiscal year ended 2018-12-31

Valuation, from the filing

Public float$88.94MMarket value of stock held by non-affiliates, as stated on the cover page for 2025-06-30
Float per share$0.08Float divided by shares outstanding in the same filing. A floor under the share price on that date, not the price itself.

Every figure here is drawn from the 10-K cover page and the statements behind it, so each one traces to a filing. Public float counts only stock held by non-affiliates, which makes these floors rather than estimates: a high multiple is conclusive, a low one may mean cheap or may mean closely held. The float was measured on 2025-06-30, not today.

Kraig Biocraft Laboratories, Inc. (KBLB) reported revenue of $401.62K and net income of -$1.17M for the fiscal year ended 2018-12-31. This page shows 5 annual periods of income statement, balance sheet and cash flow figures normalized from Kraig Biocraft Laboratories, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Plastic Material, Synth Resin/Rubber, Cellulos (No Glass).

Income

Kraig Biocraft Laboratories, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2018-12-312017-12-312016-12-312015-12-312014-12-31
Revenue$401.62K$97.32K$31.86K$0$0
Cost of revenueUnavailableUnavailableUnavailableUnavailableUnavailable
Gross profitUnavailableUnavailableUnavailableUnavailableUnavailable
Operating income-$959.95K-$2.16M-$2.95M-$2.05M-$1.83M
Net income-$1.17M-$2.33M-$3.07M-$2.13M-$1.87M
Research & development$148.07K$258.89K$397.14K$432.01K$439.54K
Weighted-average diluted sharesUnavailableUnavailableUnavailableUnavailableUnavailable
Pretax income-$1.17M-$2.33M-$3.07M-$2.13M-$1.87M
Income tax expense$0$0$0$0$0
Diluted EPSUnavailableUnavailableUnavailableUnavailableUnavailable
Selling, general & administrativeUnavailableUnavailableUnavailableUnavailableUnavailable
General & administrative$515.88K$1.22M$1.74M$920.92K$896.08K
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

Kraig Biocraft Laboratories, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2018-12-312017-12-312016-12-312015-12-312014-12-31
Cash & equivalents$13.70K$18.15K$298.86K$238.19K$495.04K
Total assets$71.38K$114.50K$383.66K$304.94K$539.23K
Current assets$20.56K$48.49K$331.79K$238.83K$496.04K
Total liabilities$4.53MUnavailable$2.74M$2.20MUnavailable
Current liabilities$4.53M$3.49M$2.74M$2.20M$1.76M
Total equity incl. NCI-$4.46M-$3.38M-$2.36M-$1.90M-$1.23M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailable
InventoryUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts receivableUnavailable$25.87K$31.86K$0Unavailable
GoodwillUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts payableUnavailableUnavailableUnavailableUnavailableUnavailable

Cash flow

Kraig Biocraft Laboratories, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2018-12-312017-12-312016-12-312015-12-312014-12-31
Operating cash flow-$235.00K-$729.54K-$1.01M-$967.56K-$904.56K
Capital expenditures$11.45K$31.17K$2.49K$39.28K$41.80K
Investing cash flow-$11.45K-$31.17K-$2.49K-$39.28K-$41.80K
Financing cash flow$242.00K$480.00K$1.08M$750.00K$1.15M
Net change in cash-$4.45K-$280.71K$60.67K-$256.85K$199.66K
Stock-based compensationUnavailableUnavailableUnavailableUnavailableUnavailable
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortization$26.63K$20.29K$16.97K$15.42K$7.16K

Derived

Kraig Biocraft Laboratories, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2018-12-312017-12-312016-12-312015-12-312014-12-31
Free cash flow-$246.45K-$760.71K-$1.01M-$1.01M-$946.36K
Gross marginUnavailableUnavailableUnavailableUnavailableUnavailable
Operating margin-239.0%-2215.4%-9246.0%UnavailableUnavailable
FCF margin-61.4%-781.7%-3183.9%UnavailableUnavailable
SBC / revenueUnavailableUnavailableUnavailableUnavailableUnavailable
Current ratio0.00x0.01x0.12x0.11x0.28x
Revenue YoY growth312.7%205.5%UnavailableUnavailableUnavailable
Net margin-291.1%-2397.4%-9648.6%UnavailableUnavailable
R&D / revenue36.9%266.0%1246.6%UnavailableUnavailable
CapEx / revenue2.9%32.0%7.8%UnavailableUnavailable
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open KBLB in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-13View SEC filing
10-Q · Filed 2026-05-14View SEC filing
10-K · Filed 2026-03-30View SEC filing
10-Q · Filed 2025-11-12View SEC filing
10-Q · Filed 2025-08-14View SEC filing
10-Q · Filed 2025-05-15View SEC filing

Companies in the same industry

CE CTA.PB

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.